Evidence map›Paper›PMID 36817441›Full record

ArticleFrontiers in immunology2023

Persistence of spike-specific immune responses in BNT162b2-vaccinated donors and generation of rapid

Sarra Mestiri, Maysaloun Merhi, Varghese P Inchakalody, Nassiba Taib, Maria K Smatti, Fareed Ahmad, Afsheen Raza, Fatma H Ali, Shereena Hydrose, Queenie Fernandes and 20 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 4 institutions in 2 countries.

Sarra MestiriTranslational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
Maysaloun MerhiTranslational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
Varghese P InchakalodyTranslational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
Nassiba TaibTranslational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
Maria K SmattiQatar University Biomedical Research Center, Qatar University, Doha, Qatar.
Fareed AhmadTranslational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.
Afsheen RazaTranslational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
Fatma H AliQatar University Biomedical Research Center, Qatar University, Doha, Qatar.
Shereena HydroseTranslational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
Queenie FernandesTranslational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
Abdul W AnsariTranslational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.
Fairooz SahirTranslational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.
Lobna Al-ZaidanTranslational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
Munir JalisTranslational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
Mokhtar GhoulTranslational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
Niloofar AllahverdiTranslational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
Mohammed U Al HomsiNational Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Shahab UddinTranslational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.
Andrew Martin JeremijenkoCommunicable Disease Center, Hamad Medical Corporation, Doha, Qatar.
Mai NimirCommunicable Disease Center, Hamad Medical Corporation, Doha, Qatar.
Laith J Abu-RaddadInfectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation-Education City, Doha, Qatar.
Fatma Ben AbidCommunicable Disease Center, Hamad Medical Corporation, Doha, Qatar.
Ahmed ZaqoutCommunicable Disease Center, Hamad Medical Corporation, Doha, Qatar.
Sameer R AlfheidCommunicable Disease Center, Hamad Medical Corporation, Doha, Qatar.
Hassan Mohamed Hassan SaqrStaff Medical Center, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
Ali S OmraniCollege of Medicine, Qatar University, Doha, Qatar.
Ali Ait HssainMedical Intensive Care Unit, Hamad Medical Corporation, Doha, Qatar.
Muna Al MaslamaniCommunicable Disease Center, Hamad Medical Corporation, Doha, Qatar.
Hadi M YassineQatar University Biomedical Research Center, Qatar University, Doha, Qatar.
Said DermimeTranslational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
Hamad Medical Corporation · QANational Center for Cancer Care and Research · QAQatar University · QAWeill Cornell Medical College in Qatar · QA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The BNT162b2 mRNA-based vaccine has shown high efficacy in preventing COVID-19 infection but there are limited data on the types and persistence of the humoral and T cell responses to such a vaccine. Methods: Here, we dissect the vaccine-induced humoral and cellular responses in a cohort of six healthy recipients of two doses of this vaccine. Results and discussion: Overall, there was heterogeneity in the spike-specific humoral and cellular responses among vaccinated individuals. Interestingly, we demonstrated that anti-spike antibody levels detected by a novel simple automated assay (Jess) were strongly correlated (r=0.863, P<0.0001) with neutralizing activity; thus, providing a potential surrogate for neutralizing cell-based assays. The spike-specific T cell response was measured with a newly modified T-spot assay in which the high-homology peptide-sequences cross-reactive with other coronaviruses were removed. This response was induced in 4/6 participants after the first dose, and all six participants after the second dose, and remained detectable in 4/6 participants five months post-vaccination. We have also shown for the first time, that BNT162b2 vaccine enhanced T cell responses also against known human common viruses. In addition, we demonstrated the efficacy of a rapid ex-vivo T cell expansion protocol for spike-specific T cell expansion to be potentially used for adoptive-cell therapy in severe COVID-19, immunocompromised individuals, and other high-risk groups. There was a 9 to 13.7-fold increase in the number of expanded T cells with a significant increase of anti-spike specific response showing higher frequencies of both activation and cytotoxic markers. Interestingly, effector memory T cells were dominant in all four participants' CD8+ expanded memory T cells; CD4+ T cells were dominated by effector memory in 2/4 participants and by central memory in the remaining two participants. Moreover, we found that high frequencies of CD4+ terminally differentiated memory T cells were associated with a greater reduction of spike-specific activated CD4+ T cells. Finally, we showed that participants who had a CD4+ central memory T cell dominance expressed a high CD69 activation marker in the CD4+ activated T cells.

Indexed as

COVID-19Immunotherapy, AdoptiveBNT162 VaccineCD4-Positive T-LymphocytesHumansImmunologic MemoryPilot ProjectsT-LymphocytesBNT162 VaccineCOVID-19 vaccineSARS-CoV-2spike-specific immune responsesspike-specific T cells expansionsurrogate neutralization

Identifiers

PMID36817441
PMCPMC9933868
OpenAlexW4318976624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.